CURIS2025-10-012026-03-31CURIS2026-03-31CURIS2025-03-31CURIS2025-04-012026-03-31CURIS2025-10-012026-03-31in-capmkt:OtherExpenses1MemberCURIS2025-04-012026-03-31in-capmkt:OtherExpenses1MemberCURIS2026-03-31OtherCurrentLiabilitiesDomain1CURIS2026-03-31OtherNoncurrentAssetsDomain1CURIS2025-10-012026-03-31RelatedPartyTransactionDomain1CURIS2025-09-30RelatedPartyTransactionDomain1CURIS2026-03-31RelatedPartyTransactionDomain1CURIS2025-10-012026-03-31RelatedPartyTransactionDomain2CURIS2025-09-30RelatedPartyTransactionDomain2CURIS2026-03-31RelatedPartyTransactionDomain2CURIS2025-10-012026-03-31RelatedPartyTransactionDomain3CURIS2025-09-30RelatedPartyTransactionDomain3CURIS2026-03-31RelatedPartyTransactionDomain3CURIS2025-10-012026-03-31RelatedPartyTransactionDomain4CURIS2025-09-30RelatedPartyTransactionDomain4CURIS2026-03-31RelatedPartyTransactionDomain4CURIS2025-10-012026-03-31RelatedPartyTransactionDomain5CURIS2025-09-30RelatedPartyTransactionDomain5CURIS2026-03-31RelatedPartyTransactionDomain5CURIS2025-10-012026-03-31RelatedPartyTransactionDomain6CURIS2025-09-30RelatedPartyTransactionDomain6CURIS2026-03-31RelatedPartyTransactionDomain6CURIS2025-10-012026-03-31RelatedPartyTransactionDomain7CURIS2025-09-30RelatedPartyTransactionDomain7CURIS2026-03-31RelatedPartyTransactionDomain7CURIS2025-10-012026-03-31RelatedPartyTransactionDomain8CURIS2025-09-30RelatedPartyTransactionDomain8CURIS2026-03-31RelatedPartyTransactionDomain8CURIS2025-10-012026-03-31RelatedPartyTransactionDomain9CURIS2025-09-30RelatedPartyTransactionDomain9CURIS2026-03-31RelatedPartyTransactionDomain9CURIS2025-10-012026-03-31RelatedPartyTransactionDomain10CURIS2025-09-30RelatedPartyTransactionDomain10CURIS2026-03-31RelatedPartyTransactionDomain10CURIS2025-10-012026-03-31RelatedPartyTransactionDomain11CURIS2025-09-30RelatedPartyTransactionDomain11CURIS2026-03-31RelatedPartyTransactionDomain11CURIS2025-10-012026-03-31RelatedPartyTransactionDomain12CURIS2025-09-30RelatedPartyTransactionDomain12CURIS2026-03-31RelatedPartyTransactionDomain12CURIS2025-10-012026-03-31AuditorDomain1CURIS2026-03-31Statement1CURIS2025-10-012026-03-31Statement1CURIS2026-03-31StatementDynamic1I1Statement1CURIS2026-03-31StatementDynamic1I2Statement1CURIS2026-03-31StatementDynamic1I3Statement1CURIS2026-03-31StatementDynamic1I4Statement1CURIS2026-03-31StatementDynamic1I5Statement1CURIS2026-03-31StatementDynamic1I6Statement1CURIS2026-03-31StatementDynamic1I7Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares000000CURISNOTLISTEDINE1BZN01016Curis Lifesciences LimitedSMEEquity2025-04-012026-03-312026-05-302026-05-30INRLakhsHalf YearlyYearlySingle segmentManufacturing of Pharmaceutical Products2026-05-3016:30:002026-05-3017:30:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNANAfalsetrue2024-12-03https://curisls.com/wp-content/uploads/B.-Policy-on-Related-Party-Transaction-1.pdftrue1falseNot Applicable2025-10-012026-03-31AuditedStandalone327199000280300033000200024604000034874000-4761600018987000708600035450002349900028641500043587000-1470004344000004344000016329000570001638600027054000000270540002705400080844000104.014.01Textual Information (4)2025-04-012026-03-31AuditedStandalone606288000281500060910300045220300035161000-68206000361740001138500069610003966100051333900095764000-147000956170000956170002632900012400026453000691640000006916400069164000808440001039273300010.2610.26Textual Infomation (1)Textual Information (2)Textual information (3)Other Expenses23499000Other Expenses396610008084400039273300004735770000055795000113340004670006759600016011400081806000081806000756900024546000274035000815208000121045000012104500050000027070001238020000341088000112226000316520000206440000691406000815208000Textual Information (1)Other current liabilities7569000Other non-Current Assests27070001138500069610000-7000120000-2356000-880000015883000-157090000-36385000-1557820002180800074612000-205000-253042000-237159000-141542000000226180000-16416000000-16416000000000000200000180190000000001200023560000-4340000-1588500000-1588500023923700000019191000011385000002086610000020866100028616000028616000303600031652000CURIS LIFESCIENCES LIMITED******Jaimik Mansukhbhai Patel******Whole Time DirectorRemunerationNA125000001250000CURIS LIFESCIENCES LIMITED******Dharmesh D Patel******Managing DirectorRemunerationNA125000001250000CURIS LIFESCIENCES LIMITED******Piyush G Antala******Whole Time DirectorRemunerationNA125000001250000CURIS LIFESCIENCES LIMITED******Biocare Formulation******Entity in which directors are interestedPurchase of goods or servicesNA47500000CURIS LIFESCIENCES LIMITED******Biocare Formulation******Entity in which directors are interestedSale of goods or servicesNA3640001190007000CURIS LIFESCIENCES LIMITED******Biocare Formulation******Entity in which directors are interestedLoanNA307000000CURIS LIFESCIENCES LIMITED******Dharmesh D Patel******Managing DirectorLoanNA3310001385500013524000CURIS LIFESCIENCES LIMITED******Jaimik Mansukhbhai Patel******Whole Time DirectorLoanNA66000078360007176000CURIS LIFESCIENCES LIMITED******Piyush G Antala******Whole Time DirectorLoanNA3500001517100014821000CURIS LIFESCIENCES LIMITED******Siddhant Jayantibhai Pawasia******DirectorLoanNA035860003586000CURIS LIFESCIENCES LIMITED******Mansukhbhai Gokaldas Patel******Relative of DirectorLoanNA046880004688000CURIS LIFESCIENCES LIMITED******Jayantibhai Dayaljibhai Pawasia******Relative of DirectorLoanNA0600000060000009000000AuditedtrueB.T. Vora & Co.true2026-02-28Public Issues2025-11-142752000002026-03-31falsefalseNANANADHARMESH DASHARATHBHAI PATELChief Financial OfficerAhmedabad2026-07-03Capital Expenditure towards Upgradation/Improvement of our existing Manufacturing FacilitiesNot Applicable24427000000Capital Expenditure towards Construction of a Storage FacilityNot Applicable361990000100000000Prepayment/Repayment of outstanding Secured LoansNot Applicable186450000182330000Product Registrations in other countriesNot Applicable26930000000Funding our Working Capital RequirementsNot Applicable11250000001125000000General Corporate PurposeNot Applicable284990000289110000Issue Related ExpensesNot Applicable280000000359630000During the period under consideration, the company incurred excess amount of Rs. 79.63 lacs for Issue Related Expenses and same is not considered for negative amount in unutilized amount. Also, EMI of Rs. 4.12 lacs were debited by the bank in period between filing of offer document and receipt of issue proceeds, therefore, that amount of shortfall in 'Pre-payment/Repayment of outstanding Secured Loans' purpose is reflected in 'General Corporate Purpose'. Further, during the period the company has made several advance payments in relation to above purposes but due Bill/Invoice not being received, it shall be considered as utilized only upon accounting of such Asset/Expenses against those advances paid.